Article Text

Download PDFPDF
Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age
  1. Gavin Clunie
  1. Department of Rheumatology, The Ipswich Hospital, Ipswich, UK
  1. Correspondence to: Gavin Peter Ross Clunie
    Department of Rheumatology, The Ipswich Hospital, Heath Rd, Ipswich, Suffolk IP4 5PD, UK; gavin.clunie{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Postmenopausal osteoporosis (PMO) related fractures are common, preventable and costly. Their prevention is a goal for healthcare agencies worldwide. Data to support screening of women are however weak and controversy surrounds whether to screen and, if so, at what age? The recommendation for, and justification of, resources for screening depends importantly on the cost-effectiveness of any screening method compared with alternatives including no screening.

The cost-effectiveness of screening needs to be considered within a complex landscape of medicosocial, financial and practical issues relevant to the healthcare system in which it operates. Accordingly, this analysis by Nayak et al is the most comprehensive attempt to date, to model the costs of screening for PMO.


The models estimated the costs (US$) of various screening methods …

View Full Text


  • Competing interests None.